• +1-646-491-9876
    • +91-20-67278686

    Search

    Hypoparathyroidism Pipeline Review H1 2017

    Hypoparathyroidism Pipeline Review H1 2017

    • Report Code ID: RW0001799285
    • Category Pharmaceuticals
    • No. of Pages 43
    • Publication Month May-17
    • Publisher Name Global Markets Direct
    Hypoparathyroidism - Pipeline Review, H1 2017

    Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Hypoparathyroidism - Pipeline Review, H1 2017, provides an overview of the Hypoparathyroidism (Hormonal Disorders) pipeline landscape.

    Hypoparathyroidism is decreased function of the parathyroid glands with underproduction of parathyroid hormone. This leads to low levels of calcium in the blood, often causing cramping and twitching of muscles (involuntary muscle contraction) , and several other symptoms. The condition can be inherited, but it is also encountered after thyroid or parathyroid gland surgery, and it can be caused by immune system-related damage as well as a number of rarer causes. The treatment includes artificial form of the hormone that can be administered as replacement, calcium replacement or vitamin.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Hypoparathyroidism - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Hypoparathyroidism (Hormonal Disorders) , complete with analysis by stage of development, drug target, mechanism of action (MoA) , route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Hypoparathyroidism (Hormonal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Hypoparathyroidism and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 1, 2 and 5 respectively.

    Hypoparathyroidism (Hormonal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Hypoparathyroidism (Hormonal Disorders) .
    - The pipeline guide reviews pipeline therapeutics for Hypoparathyroidism (Hormonal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Hypoparathyroidism (Hormonal Disorders) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Hypoparathyroidism (Hormonal Disorders) therapeutics based on mechanism of action (MoA) , drug target, route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Hypoparathyroidism (Hormonal Disorders)

    Reasons to buy

    - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Hypoparathyroidism (Hormonal Disorders) .
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Hypoparathyroidism (Hormonal Disorders) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents
    List of Tables
    List of Figures
    Introduction
    Publisher Report Coverage
    Hypoparathyroidism - Overview
    Hypoparathyroidism - Therapeutics Development
    Pipeline Overview
    Pipeline by Companies
    Products under Development by Companies
    Hypoparathyroidism - Therapeutics Assessment
    Assessment by Target
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Hypoparathyroidism - Companies Involved in Therapeutics Development
    Ascendis Pharma A/S
    Chugai Pharmaceutical Co Ltd
    Eli Lilly and Company
    Entera Bio Ltd
    Pharis Biotec GmbH
    Shire Plc
    Hypoparathyroidism - Drug Profiles
    hPTH-137 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    parathyroid hormone - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    PCO-371 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Protein to Agonize Parathyroid Hormone Receptor for Hypoparathyroidism - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    PTH-RM - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Recombinant Protein to Agonize PTHR1 for Hypoparathyroidism - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Synthetic Peptide to Agonize PTH1R and PTH2R for Hypoparathyroidism - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    teriparatide - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Hypoparathyroidism - Dormant Projects
    Hypoparathyroidism - Product Development Milestones
    Featured News & Press Releases
    Apr 26, 2017: Shire Granted EU Conditional Marketing Authorisation for Natpar (Parathyroid Hormone) for the Treatment of Patients with Chronic Hypoparathyroidism
    Apr 03, 2017: Ascendis Pharma Presents Data on TransCon PTH at ENDO 2017
    Feb 28, 2017: Ascendis Pharma Announces Data on TransCon PTH at ENDO 2017
    Feb 24, 2017: First hormone replacement therapy for parathyroid disorder
    Jun 29, 2016: EnteraBio Receives Orphan Drug Approval for PTH 1-34 from European Medicines Agency
    Jul 22, 2015: Entera Bio Announces Phase II Results of PTH 1-34 in Treating Hypoparathyroidism
    Jan 23, 2015: FDA approves Natpara to control low blood calcium levels in patients with hypoparathyroidism
    Dec 02, 2014: European Medicines Agency Validates Marketing Authorization Application for Natpar (parathyroid hormone (rDNA) ) in Hypoparathyroidism
    Oct 23, 2014: PDUFA Action Date For Natpara BLA Extended Three Months To January 24, 2015
    Sep 12, 2014: FDA Advisory Committee Recommends Approval of Natpara for Long-Term Treatment of Hypoparathyroidism
    Sep 12, 2014: FDA Advisory Committee to Review Natpara Biologics License Application
    Sep 10, 2014: FDA Posts Briefing Materials for Advisory Committee Meeting Reviewing Natpara for Hypoparathyroidism
    Jul 24, 2014: PARADOX Findings Published in Endocrine Practice Describe High Burden of Illness in Patients with Hypoparathyroidism
    Jun 10, 2014: NPS Pharma Reports Change in Tentative Date of FDA Advisory Committee Review of Natpara BLA to September 12 - PDUFA Date of October 24 Remains Unchanged
    Jan 07, 2014: NPS Pharmaceuticals Announces FDA Acceptance of Biologics License Application for Natpara for the Treatment of Hypoparathyroidism
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer

    List of Tables

    Number of Products under Development for Hypoparathyroidism, H1 2017
    Number of Products under Development by Companies, H1 2017
    Products under Development by Companies, H1 2017
    Number of Products by Stage and Target, H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Hypoparathyroidism - Pipeline by Ascendis Pharma A/S, H1 2017
    Hypoparathyroidism - Pipeline by Chugai Pharmaceutical Co Ltd, H1 2017
    Hypoparathyroidism - Pipeline by Eli Lilly and Company, H1 2017
    Hypoparathyroidism - Pipeline by Entera Bio Ltd, H1 2017
    Hypoparathyroidism - Pipeline by Pharis Biotec GmbH, H1 2017
    Hypoparathyroidism - Pipeline by Shire Plc, H1 2017
    Hypoparathyroidism - Dormant Projects, H1 2017

    List of Figures

    Number of Products under Development for Hypoparathyroidism, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products by Targets, H1 2017
    Number of Products by Stage and Targets, H1 2017
    Number of Products by Mechanism of Actions, H1 2017
    Number of Products by Stage and Mechanism of Actions, H1 2017
    Number of Products by Routes of Administration, H1 2017
    Number of Products by Stage and Routes of Administration, H1 2017
    Number of Products by Molecule Types, H1 2017
    Number of Products by Stage and Molecule Types, H1 2017
    Ascendis Pharma A/S
    Chugai Pharmaceutical Co Ltd
    Eli Lilly and Company
    Entera Bio Ltd
    Pharis Biotec GmbH
    Shire Plc

    Request for Sample

    Report Url http://www.reportsweb.com//hypoparathyroidism-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//hypoparathyroidism-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//hypoparathyroidism-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments